Physician profile
Michael Kanner
NPI 1134184740
$3,036.86
in general payments reported to CMS, 2019-2025
17 companies · $709 in 2025
The $709 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.69 · 2020: $122 · 2021: $193 · 2022: $642 · 2023: $570 · 2024: $765 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $719.26 | 2021-2025 | Eysuvis, Clareon, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $464.65 | 2020-2025 | Cequa |
| Bausch & Lomb Americas INC. | $422.91 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $217.44 | 2020-2022 | |
| Abbott Laboratories | $199.50 | 2024 | Epic |
| Thea Pharma INC. | $173.00 | 2023-2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $127.39 | 2022-2023 | Flarex |
| Glaukos Corporation | $115.39 | 2021-2025 | Idose, Idosetr, Istent Infinite |
| Tarsus Pharmaceuticals, INC. | $98.88 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $98.43 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $77.51 | 2019-2021 | |
| Abbvie INC. | $76.87 | 2024-2025 | |
| Dompe US, INC. | $76.74 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $64.59 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rayner Intraocular Lenses Limited | $59.58 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $23.12 | 2024 | Vevye |
| Santen INC. | $21.60 | 2023 | Verkazia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.